, Tracking Stock Market Picks
Enter Symbol:
Rating: MDVN
Buy $148
down 16.00 %

MEDIVATION INC (NASDAQ: MDVN) reiterated to Buy with price target $148 by UBS

Tuesday,  Aug 25, 2015  10:25 AM ET by Betsy O'Brien Harrison

UBS reiterated MEDIVATION INC (NASDAQ: MDVN) to Buy with price target $148. Previously UBS reiterated MEDIVATION INC (NASDAQ: MDVN) to Buy with price target
$125 on 12/15/2014, when the stock price was $103.38. Since then, MEDIVATION INC's stock price has lost 16% as of 08/25/2015's recent price of $86.38.
If you would have followed the previous UBS's recommendation on MDVN, you would have lost 16% of your investment in 253 days.

Medivation, Inc. is a biopharmaceutical company with small molecule drugs in clinical development to treat three medical needs: Alzheimer?s disease, Huntington?s disease and castration-resistant prostate cancer. The Company has formed separate subsidiaries to hold the product candidates it is developing. The Company?s subsidiary Medivation Neurology, Inc. holds its Dimebon technology, and its subsidiary Medivation Prostate Therapeutics, Inc. holds its MDV300 series technology.

UBS is the leading global wealth manager, a top tier investment banking and securities firm, and one of the largest global asset managers. In Switzerland, UBS is the market leader in retail and commercial banking. With headquarters in Zurich and Basel, Switzerland, UBS operates in over 50 countries and from all major international centers. UBS employs more than 80,000 people.

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy